The pull-back of insurance providers has left state-run health exchanges and the Obama administration facing a difficult communications challenge.
The impending payer crackdown of the cost of MS drugs could portend the fate of other specialty drug markets, according to analysts.
Express Scripts and CVS Health revealed their formularies with Pfizer's Xeljanz making the jump from excluded to preferred for Express Scripts.
States and insurers are lifting restrictions on HCV drugs; Teva's request to join PhRMA raises eyebrows; Merck partners with GPO
UnitedHealthcare this month launched a year-long campaign, called Hay Más Adelante.
Cigna signs value contracts for new cholesterol drugs; Yelp partners with ProPublica for hospital reviews; ad-blocking threat to digital publishers intensifies
The drugmaker instead suggested using an economic model it developed.
OptumRx partners with Walgreens Boots Alliance; Turing's former lawyer said Daraprim price hike was unjustified; the White House names moonshot leader
Novo's Tresiba gets non-preferred status; Valeant's head of dermatology and gastrointestinal products resigns; Trump plans to allow importation of drugs from abroad
The pharmaceutical company reported a 2% revenue increase in 2015, and diabetes medication is a key contributor.
In many cases, the drug required physicians to request prior authorization.
Britain says Bristol-Myers Squibb's Opdivo is too expensive; Calpers reports 32% boost in specialty drug spending; NIH is funding fewer clinical trials
UnitedHealth gives Praluent preferred status on its formularies; Stat News examines the first DTC drug ad; Britain to cover Entresto
Some pharma companies are taking steps to address concerns about the high prices of drugs at a time when Democratic lawmakers are urging price controls.
More patients may be eligible for new PCSK9 inhibitors; Collegium's painkiller may receive FDA approval; MannKind's Afrezza reports slow sales
Obama administration tells states they cannot restrict hep-C drugs; AstraZeneca says it will acquire ZS Pharma: Allergan CEO says drug discovery is too risky
The drugmaker said Entresto, its new heart-failure drug, brought in "modest sales" in the third quarter of 2015.
Attention turns to Valeant, which is facing subpoenas from two attorneys general who are seeking information about the drugmaker's patient-assistance, drug-pricing and drug-distribution practices.
The pharmacy benefit manager included both PCSK9 inhibitors on its national formulary. Spending on the drugs is estimated to reach $750 million in 2016.
The FDA approves another generic version of Abilify; drug price increases driving profit growth; Spark plans to submit eye-drug to the FDA in 2016
The FDA approves Opdivo/Yervoy combination to treat melanoma; BioMarin acquires global rights to Kuvan; Allergan's Juvederm receives marketing approval for lip augmentation
Teva exec says pharma needs to pay attention to its reputation; academics who serve on boards of healthcare companies face potential conflicts of interest; WHO recommendation will boost number of people taking anti-retrovirals
A panel composed of physicians and medical researchers expressed caution in prescribing PCSK9 inhibitors for off-label uses.
Clinton expecting to discuss drug prices; Turing criticized for raising the price of infectious-disease drug; online game helps patients reduce blood pressure
Entresto's price is too high; Shire may increase its bid for Baxalta; Sanofi's experimental diabetes drug LixiLan met its late-stage trial target
Amgen's Repatha receives FDA nod; Mylan shareholders vote in favor of Perrigo deal; doctors push for below-average price of experimental cancer drug
Medicaid officials urged to expand access to hepatitis-C drugs; Perrigo is looking to make acquisitions; Sarepta's experimental therapy gets priority review
The pharmacy benefit manager said that the introduction of new treatments and clinical evidence on statins demands a rethink to ACC/AHA guidelines
CVS will not negotiate PCSK9 inhibitor pricing until Amgen's Repatha receives approval; more companies are looking inward for marketing help in lieu of agencies; AstraZeneca inks oncology collaboration
The Danish drugmaker said it expects an FDA decision about long-acting—and long-delayed—insulin Tresiba in October.
The PBM said AstraZeneca's diabetes medications Onglyza and Kombiglyze XR will not be covered next year.
The promise of an Opdivo/Yervoy combination, now awaiting FDA approval, has more to do with payer strategy than efficacy, analysts say.
UnitedHealth Group buys PBM Catamaran; Sanofi launches Toujeo; Teva acquires Auspex Pharmaceuticals
Here's three items you need to know from our latest managed markets/payer feature: Formulary Fireworks
In a bid to compete with CVS Caremark, pharmacy retailer Rite Aid has purchased pharmacy- benefit manager Envision Pharmaceutical Services.
Express Scripts takes aim at high-priced cancer drugs; FDA panel recommends approval for Astellas orphan drug; GSK Ebola Vaccine could touch down in Liberia as early as next week.
A deal struck by the drugmaker calls for state HIV programs to access its HCV combo, Viekira Pak, at a significant discount.
Transitional pass-through reimbursement status clears way for commercialization.
- The 2017 pipeline report: What to know about next year's launches
- Five things for pharma marketers to know: Monday, November 28, 2016
- Lilly's branded app for Trulicity looks to address adherence
- Lawmakers cut CME exemption from 21st Century Cures Act
- Five things for pharma marketers to know: Tuesday, November 29, 2016
- Boehringer Ingelheim launches gamified support program
- Omnicom merges AgencyRx, Flashpoint and three other agencies to form DDB Health
- No free lunch for docs: Sponsored meals linked to more prescriptions
- Non-profit behind Free Killer Tan wants parents to practice sun safety
- Allergan draws on A-list celebs to drive engagement
- Prescription drug spending rises 9% in 2015, to $324 billion
- As users move to mobile, Google says they made 200 million queries for info about cancer drugs
- Five things for pharma marketers to know: Friday, December 2, 2016
- Mylan CEO defends EpiPen strategy, questions pricing model in the U.S.
- Five things for pharma marketers to know: Thursday, December 1, 2016